Science Trends
No Result
View All Result
  • Health
  • Earth & Environment
  • Space
  • Technology
  • Mind
  • Matter & Energy
Science Trends
Engineering T Cell Receptors To Reduce The Risk Of Adverse Side Effects In Immunotherapy
Share This:
Science Trends
No Result
View All Result

Engineering T Cell Receptors To Reduce The Risk Of Adverse Side Effects In Immunotherapy

by Brian Baker, Tim Riley & David Hardwicke
March 27, 2018
0
Credit: Wikimedia Commons

Credit: Wikimedia Commons

Engineered T cells represent a new and novel approach to target cancer. By introducing unique antigen targeting molecules, we can redirect T cells to locate and destroy cancer cells within the body.

Researchers have been studying ways to use T cells, at the heart of cellular immunity, and the body’s immune system to fight cancer since the 1980s. The antigen targeting molecules in these early studies were tumor-specific T cell receptors (TCRs) targeting tumor-associated peptides presented on the cell surface – but the results revealed a challenge researchers are still working to solve. While TCRs can target peptides of specific disease indications, there is also the potential for autoimmune toxicity. If not carefully controlled, TCRs can direct T cells to healthy cells as well as cancer cells, with potentially fatal consequences.

The process through which the TCR identifies its target, as we understand now, is far more complex than once believed. There are a number of things to consider including utilization of complementarity determining region (CDR) loops, the role of the target peptide/antigen, and the structural complexities of multi-component signaling.

Our approach aims to modify the physical properties of tumor-specific, clinically relevant TCRs by perturbing their structure. In the context of cell therapy, the objective is to improve the ‘fit’ between the target antigen and the TCR. This structure-guided approach to T cell engineering differs from other brute force methods, which aim to screen thousands of TCRs to identify the one with desired properties.

The use of this method allows us to do something very unique: modulate specificity. Because we study the structural properties of these target antigens, it is possible for us to design TCRs with complementary features, similar to a peg in a hole. Therefore, this technique allows us to not only identify TCRs with poor antigen specificity (and thus, be dangerous as a therapeutic) but mitigate such unwanted recognition by improving complementarity with the tumor-associated antigen.

However, a challenging component of a structure-guided design strategy is the construction of accurate computational models. These models not only have to predict the correct conformation of the redesigned TCR but must also predict the measured impact on antigen recognition.

Regardless, the benefits of a structure-guided strategy combine to result in a method that it is disease-agnostic. Once you have constructed a model that accounts for the unique elements of TCR recognition, you can deploy it against a wide array of cancer types and diseases. Most of our work emphasizes melanoma, but we have deployed our model to improve TCRs targeting myeloma and lymphoma as well.

With the T cell therapy industry continuing to grow and evolve at a rapid pace, we saw an opportunity to commercialize our research and form a company. In August 2017, we started Structured Immunity with a clear mission: to accelerate and improve the development of TCRs for T cell therapies. We partner with leading biopharmaceutical companies and deploy our technology to optimize their receptors.

Although the FDA has approved T cell therapies using other antigen targeting molecules (Chimeric Antigen Receptors, or CARs), these molecules have limited applicability to solid tumors. Researchers are actively studying TCRs to treat these diseases, but the identification of safe TCRs hinders this next development of cell therapy. By leveraging our novel approach to engineering TCRs, we hope to support the next generation of T cell therapies focused on solid tumors.

This article is based on work conducted by Brian Baker from the University of Notre Dame with Tim Riley and David Hardwicke from Structured Immunity.

About The Author

Brian Baker

Brian Baker is a Rev. John A. Zahm Professor and Department Chair at the University of Notre Dame | ND · Department of Chemistry and Biochemistry.

Tim Riley

Protein Engineer and Scientist at Amgen and Chief Science Officer at Structure Immunity.

David Hardwicke

David Hardwicke is President of Structure Immunity and Senior Project Manager at AveXis, Inc.

.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Trevor Nace

Science Trends connects scientists and their research with a global audience.

Trevor Nace - PhD & Founder
Share Your Research

Read This Next

Mind The Gap: The Role Of Spacing Letters In Early Reading

Hosting Capacity In Modern Power Systems: Outlooks And Challenges

Targeting PARP1 Activity May Be An Effective Treatment For Some Epstein-Barr Patients

The Dubious Increase In ADHD Diagnoses

Editor's Picks

Image by William Cho via Pixabay is licensed under CC0
Mind

Neurobiological Evidence In Sentencing Decisions: A Double-Edged Sword

by Corey H. Allen & Eyal Aharoni
February 14, 2019
Image by MatanVizel via Pixabay is licensed under CC0
Mind

Do Outcomes Or Perceptions Of Morality Influence Our Sense Of Generosity?

by Ben M. Tappin
February 14, 2019
Image by PIROD via Pixabay is licensed under CC0
Technology

If Neural Networks Are Allowed To Sleep And Dream, Their Performance Sensibly Increases

by Adriano Barra
February 14, 2019
Image by Pexels via Pixabay is licensed under CC0
Health

Recent Stressful Events Linked With Smoking During Pregnancy

by Alicia Allen
February 13, 2019

Science Trends | Explore More

Science Trends is a free platform that connects scientists and their peer-reviewed research with a global audience through self-directed press releases.

ISSN: 2639-1538 (online)

About

Advertising Policy

Contact

Editorial Policies

Privacy Policy

Share Your Research

Terms Of Service

© 2018 SCIENCE TRENDS

No Result
View All Result
  • Health
  • Earth & Environment
  • Space
  • Technology
  • Mind
  • Matter & Energy
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Accept | Read More